Use of a Pharmaceutical Combination comprising a Second linagliptin and Antidiabetic Agent selected among Thiazolidinediones, sulfonylureas, Biguanides, glinide, among others, and, Optionally, a Third Antidiabetic Agent, to treat Type 2 diabetes mellitus and diabetic complications, among others.

摘要

Pharmaceutical composition comprising a compound dpp-4 Inhibitor, and optionally an agent Group G3 of Biguanides, sulfonylureas and thiazolidinediones.Among others, and optionally a different Agent Group G3; Combination method; Pharmaceuticals; and use for treating Metabolic Disorders such as diabetes.